SCH-48461

In today's world, SCH-48461 is a topic that arouses great interest and debate in different sectors of society. The impact of SCH-48461 has been noted in areas such as economy, politics, culture and technology, generating endless different opinions and perspectives. Since its emergence, SCH-48461 has been the subject of study and research by experts in the field, who seek to understand its implications and consequences in the short, medium and long term. This article will explore the phenomenon of SCH-48461 in depth, analyzing its causes, effects and possible solutions, in order to shed light on a topic that continues to be a source of controversy and reflection today.

SCH-48461
Names
Preferred IUPAC name
(3R,4S)-1,4-Bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1 ☒N
    Key: IMNTVVOUWFPRSB-JWQCQUIFSA-N ☒N
  • InChI=1/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1
    Key: IMNTVVOUWFPRSB-JWQCQUIFBU
  • COc1ccc(cc1)2(C(=O)N2c3ccc(cc3)OC)CCCc4ccccc4
Properties
C26H27NO3
Molar mass 401.49748
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
☒N verify (what is checkY☒N ?)

SCH-48461 is a cholesterol absorption inhibitor.[1][2]

During the early phases of an NPC1L1 inhibitor discovery program at Schering-Plough, conformationally restricted analogs based on the 2-azetidinone backbone were targeted by Burnett and co-workers.[3] Early in the biological evaluation, it became apparent that even though the in vitro ACAT inhibitory activity of these analogs was modest (e.g., IC50 values of 2–50 mM), they exhibited significant activity in a cholesterol-fed hamster model (CFH). The discovery of the prototypical 2-azetidinone CAI, SCH-48461 (ACAT IC50 ~26 mM, ED50 of CE reduction in hamsters ~2.2 mpk) and the details of the first-generation SAR have been described in detail.[4]

References

  1. ^ Salisbury BG, Davis HR, Burrier RE, et al. (May 1995). "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461". Atherosclerosis. 115 (1): 45–63. doi:10.1016/0021-9150(94)05499-9. PMID 7669087.
  2. ^ Dujovne CA, Bays H, Davidson MH, et al. (January 2001). "Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study". J Clin Pharmacol. 41 (1): 70–8. doi:10.1177/00912700122009854. PMID 11144997. S2CID 30737100.
  3. ^ Burnett, Duane A. (1994). "2-Azetidinones as Inhibitors of Cholesterol Absorption". Journal of Medicinal Chemistry. 37 (12): 1733–1736. doi:10.1021/jm00038a001. PMID 8021912.
  4. ^ Clader, John W. (1996). "2-Azetidinone Cholesterol Absorption Inhibitors: Structure−Activity Relationships on the Heterocyclic Nucleus". Journal of Medicinal Chemistry. 39 (19): 3684–3693. doi:10.1021/jm960405n. PMID 8809157.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.